PAREXEL Expands Industry-Leading Perceptive® Partner Program with Addition of CRF Health and Clinical Ink

Life sciences service providers leverage PAREXEL's eClinical solutions to simplify drug development for customers through technology partnership initiative

BOSTON, MA – PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that clinical technology companies CRF Health and Clinical Ink have joined its Perceptive® Partner Program.  Through the program, technology, consulting, reseller and training companies, as well as contract research organizations (CROs), can enhance and broaden their services to biopharmaceutical customers by leveraging thePerceptive® MyTrials eClinical platform along with clinical and technical support services.

Perceptive® MyTrials is one of the industry's leading suites of applications for managing clinical trials. Its flexible, open architecture allows partners to integrate targeted, specialized solutions within the platform.  This gives their sponsor customers efficient access to clinical data and applications from a single source, allowing them to more efficiently and effectively manage critical trial activities.

"To better ensure the safety and timeliness of their trials, our customers are increasingly seeking efficient approaches to patient screening, enrollment and randomization," said Rachael Wyllie, CEO of CRF Health. "As a Perceptive partner, we can address these needs by integrating our electronic Clinical Outcome Assessments [eCOA] offering with Perceptive MyTrials randomization and electronic data capture technologies."

Ed Seguine, CEO of Clinical Ink, said, "Integrating solutions from Perceptive® MyTrials into our SureSource® clinical platform will provide sponsors with proven trial management solutions in a user-friendly tablet PC system.  This presents a powerful combination of functionality and mobility."

As study designs become increasingly complex, sponsors are relying on eClinical technologies to manage protocols and evolving regulatory requirements.  Developed in 2013 and consisting of an ecosystem of technology and CRO partners, the Perceptive® Partner Program offers support services and training that enable service providers to integrate their offerings with individual or collective Perceptive® MyTrials applications including:

  • DataLabs® Electronic Data Capture (EDC)
  • ClinPhone® Randomization and Trial Supply Management (RTSM)
  • IMPACT® Clinical Trial Management System (CTMS)
  • Electronic Patient Reported Outcomes (ePRO)
  • Medical Imaging
  • Perceptive MyTrials® Data-Driven Monitoring
  • LIQUENT® Insight® Regulatory Information Management
     

"Sponsors continue to seek fully integrated, best-of-breed technology solutions and clinical outsourcing services that can be efficiently managed," said Graham Bunn, Vice President, Perceptive Partner Program. "Adding CRF Health and Clinical Ink to our partner program further reinforces its value proposition as the industry's premier partnership initiative for simplifying drug development."

# # #

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 80 locations in 51 countries around the world, and has approximately 15,560 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

About CRF Health

CRF Health is a leading provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials.  With experience in more than 475 trials, over 100 languages and across 74 countries, CRF Health's TrialMax eCOA solutions consistently demonstrate the industry's highest data accuracy, patient and site compliance, and patient retention.   CRF Health's TrialMax eCOA solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance.  Their eCOA solutions include PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs (Clinician or Rater Reported Outcomes).

About Clinical Ink

With offices in Winston-Salem, NC and Philadelphia, PA, Clinical Ink is an innovation-driven eSource solutions company committed to delivering technology that makes clinical research easier for sites, sponsors, subjects and regulators. Developers of SureSource®, the first purpose-built eSource solution providing cleaner data faster, Clinical Ink is dedicated to eliminating paper documents in clinical research.

Additional information about Clinical Ink is available at www.clinicalink.com or by calling toll-free 800-301-5033.

PAREXEL, Perceptive, Perceptive MyTrials, ClinPhone, DataLabs, IMPACT, and LIQUENT are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014 as filed with the SEC on August 20, 2014, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.